CFB
ADMA icon

Cullen/Frost Bankers’s ADMA Biologics ADMA Stock Holding History

Cullen/Frost Bankers’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,383
Closed -$21.5K – 1412
2026
Q1 		$21.5K Buy
+2,383
New +$37.6K ﹤0.01% 965
2025
Q3 		– Sell
-2,042
Closed -$37.2K – 1324
2025
Q2 		$37.2K Buy
2,042
+1,081
+112% +$22K ﹤0.01% 808
2025
Q1 		$19.1K Buy
961
+134
+16% +$2.32K ﹤0.01% 855
2024
Q4 		$14.2K Buy
827
+26
+3% +$489 ﹤0.01% 831
2024
Q3 		$16K Sell
801
-41
-5% -$638 ﹤0.01% 834
2024
Q2 		$9.41K Buy
+842
New +$7.06K ﹤0.01% 851

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Cullen/Frost Bankers's ADMA Position: Q2 2026 in Review

Cullen/Frost Bankers sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 2,383 shares — an estimated $21.5K sold.

Cullen/Frost Bankers first reported a position in ADMA in Q2 2024 and held it in 6 quarters. The position peaked at $37.2K in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Cullen/Frost Bankers reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Cullen/Frost Bankers sold 2,383 ADMA Biologics shares in Q2 2026, an estimated $21.5K.
  • Cullen/Frost Bankers first reported a position in ADMA Biologics in Q2 2024 and held it in 6 quarters.
  • Cullen/Frost Bankers's ADMA Biologics position peaked at $37.2K in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.